Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So far as I can see, there is absolutely nothing about the pending acquisition of ELGL's assets. Disappointing.
They have to file the 10k by March 31, so that means this week I guess. We should see.
Oops, I guess I spoke too soon.
Well, whatever gripped the BFNH market for the last two days, seems to have passed.
Will we ever know what happened?
It's predictive biotech that is in las Vegas. That's the company that pred sold to HLTT if I remember correctly. Further down the list is Predictive Technology Group, which is still listed in Salt Lake.
Sounds like good news. The market is open for offtake agreements. The Shell agreement is for 10 million gallons over the next two years. The Jet fuel used by airlines in the US in 2021 was almost 14 BILLION gallons. In 2019, before covid, the total was over 18 billion. The worldwide total was down the last couple of years due to Covid, as well, but in 2019 it was 95 billion gallons. No shortage of demand.
There is a note of the airlines desperation in the article. If they're investing money in algae, they're investing in anything.
As to Blue, when they get this prototype up and running and tested, they can reach out for offtake agreements. I think we're in great shape. All we need as stockholders is patience.
https://www.statista.com/statistics/197690/us-airline-fuel-consumption-since-2004/#:~:text=In%202021%2C%20due%20to%20the,18.43%20billion%20gallons%20in%202007.
If you look at the filing, it's all there. He got the options from the company for services rendered, The exercisable date is listed on a column in the middle.
Pretty good day. Pretty good couple of days.
I'm not Joe, whoever he is.
because some trades are made off market or within a brokerage house. They have to be reported to the market within 15 minutes of close. You see it on every stock every day. The 100k shares were probably traded earlier in the day at the then market price and reported at 4:01 as required. This should not effect the listed close price, which should be 17.9.
Well, mazzone, forever is a long time, but we are on a wait. I'm always thinking it will be next week ... or the week after, or ...
the funny thing is that I am still confident it will happen. They still have a website up, ELGL, and I haven't heard of anyone leaving. So, maybe.
I'm not an expert, but this is my take. We'll see when the healthtech numbers come out. If PRED's pass through is substantial, I would say the chances are very good. As usual, we have to wait.
A couple of trades since your post, and the price is up to .16 or thereabouts, BUT, the volume is only 1200 shares or 192 dollars. Even I could scrap together that much, LOL.
New filing from HLTT. Looks good, some comments on HLTT board.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1307624/000126246323000012/hltt8k12723.htm
Hey, hey, all New York jerks are not typical.
This all sounds good to me. Let's see how it plays out.
Actually, you should just look at the form. They exercised old warrants from 2021 and 2019.
So, if the machine comes tomorrow, or next week, or the one after that is that no honesty? Or is in an inability to foretell the future worth certainly.
My point was that you want the company to tell you when something will happen before it happens, Not that they tell you in advance. If you get a prediction there is always a degree of uncertainty. That's the way it is. You make money in the markets by buying uncertainly, (risk), not by buying certainty.
you want information in advance and you want accurate information. Do you see the issue?
What gets old is your non-stop attacks on the company and your impatience. It's a risk reward play, either it happens or it doesn't. If it happens you get rich if not you lose what you put in.
The delivery is in the hands of Kommarck, not the biof. there are delays all over the place.
You seem to be confused about who "the company" is, or at least write as if you are. The company is not PRED, it is HLTT. PRED has not been putting out news, although I understand their reluctance given their history with the SEC and news releases. HLTT is putting out news on a regular schedule. From HLTT's news releases, we can glean at least part of what is going on with PRED. I think we'll be fine.
HLTT came out with a letter to stock holders in which it said that it sold 776k of it's wound care products in September and an increasing amount every month since in the fourth quarter. The letter is below and also filed with the SEC.
HEALTHTECH SOLUTIONS, INC.
181 Dante Avenue
Tuckahoe, New York 10707
Annual letter to our shareholders and employees
Greetings:
As the new year emerges, I am using this occasion to reflect on the progress made by your company (“HLTT”) during 2022 and the prospects that we see for 2023. We ended 2021 as a medical technology incubator with only a series of scanning technologies, all of which were a distance from potential revenue. We ended 2022 with multiple profit centers already generating substantial revenue or poised to do so.
Our growth during 2022 can be understood as expansion in three integrated vectors: expansion of technology, expansion of skills, expansion of markets. I will summarize our principal accomplishments in each.
Technology: Acquisition of Wound Care IP.
In January 2022, HLTT acquired the assets of a Utah-based biomedical company related to production of wound care treatments. These assets included an FDA licensed manufacturing facility with equipment, intellectual property, including patents, related to wound care, and a skilled management team. The team included the Laboratory Director, the Chief Laboratory Officer, the Senior Vice President of Quality and Regulatory, and the Chief Medical Officer of the manufacturing lab facility.
In the Spring of 2022, we completed the licensing of our initial wound care product line and appointed World Reach Health, LLC (“WRH”), an experienced distributor of biomedical products (more on WRH below), to develop a market for our wound care products. That market produced its first sales in September 2022, and we reported net revenue of $776,221 for that month. We have recorded increased wound care revenue for each month in the fourth quarter of 2022, and we expect wound care revenue to continue to grow during 2023.
Skills: Acquisition of World Reach Health.
Our relationship with World Reach Health grew throughout 2022, as we saw the potential for mutual benefit to HLTT and to WRH from an enhanced relationship. Jelena Olmstead and Jim Pesoli, the owners and principals of WRH, each worked closely with HLTT management to build the HLTT wound care business. They were also instrumental in establishing our new CLIA lab (see below).
In December 2022, the growth of the relationship culminated in the execution of a binding contract under which HLTT will acquire 51% of the membership interest in World Reach Holdings, the parent company of World Reach Health (WRH). The closing will occur in January 2023. WRH is a distributor of biomedical products and medical devices. It sells directly to medical professionals and also has established a nationwide network of sub-distributors.
1
The acquisition will provide HLTT assurance of access to markets for the products and services that its subsidiaries develop. Of equal significance, the acquisition will bring into HLTT management the skills and experience provided by Jelena Olmstead and Jim Pesoli. At the closing of the World Reach Holdings transaction, Jelena will become the CEO and Jim the Senior Vice President of HLTT.
Jelena Olmstead. With over 20 years of experience in distribution of medical products and services, Jelena has familiarity with all continuums of care: Acute, LTC, Home Health, Hospice and Wound Care Clinics. Jelena was intimately involved in developing of annual sales strategies and plans, developing Wound Care processes, establishing best practices, and launching many emerging products into the market, while managing national sales and operations teams. Prior to organizing World Reach Health, Jelena served as Director of Business Development for NuMotion, which specialized in medical devices for mobility needs. Jelena was personally involved in the distribution of more than $1.5 billion worth of goods annually over the course of her career. Prior to joining NuMotion, Jelena was the Business Development Director and Key Account Manager for Invacare and for Joerns, both global healthcare manufacturers and distributors of DME and medical devices. Jelena was involved in a multitude of M&As throughout her career.
Jim Pesoli. Jim’s 15 years of experience as a healthcare-services executive and transactional attorney commenced when he began negotiating international manufacturing and distribution agreements for a variety of commodities and/or intellectual property rights. Later, he founded and eventually sold, Sonic Cleaning Services, which provided housekeeping and laundry services to nursing homes, assisted living facilities and healthcare institutions throughout the Midwest. Throughout his career, Jim has maintained close relationships with the distributors and manufacturers he represented or worked with. Additionally, as an entrepreneur, Jim has raised over $100 million in venture capital for a myriad of enterprises. Within World Reach Health, Jim has been instrumental in identifying and establishing strategic partnerships and brokering long-term purchasing agreements with product suppliers and purchasers around the globe.
WRH has ongoing contracts to distribute a number of products. These include Endurakit, a non-opiate surgical block for which WRH is one of four national distributors. WRH is the exclusive distributor for MY GEL, which is a neuropathy pain gel. WRH is also an approved distributor for some of the leading COVID-19 diagnostic tests, along with other diagnostic products, which are manufactured by AccessBio and Phase Scientific. WRH is a distributor of the Postday One-Step emergency contraceptive, and WRH is also an authorized distributor of Better Air, which provides organic probiotic air purification solutions. In this fashion, we expect WRH to provide a gateway to market for the products developed by HLTT subsidiaries as well as a source of additions to HLTT’s product list.
2
Markets: Organization of The Clia Lab.
Our current business plan points towards integration of complementary product and service lines, with the goal of maximizing the potential market for products and services developed by our subsidiaries. For example, WRH is well-established as a distributor in the rapid-testing market, which includes testing for Flu, Covid and Mersa. To optimize the opportunities presented by WRH’s presence in that market, the logical next step was to organize our own lab.
In the second half of 2022, therefore, we established an FDA-licensed CLIA laboratory, appropriately named “The CLIA Lab.” This facility is housed at the University of Utah technology campus in Salt Lake City.
The CLIA Lab is licensed to perform the Flu, Covid and Mersa tests that WRH has to date sold for other labs. It is also licensed to perform bacteria testing, providing a new revenue stream for WRH as well as a market advantage for HLTT’s wound care products. We expect to offer bundle packages to our wound care providers, which will include both the clinical test required prior to a wound care treatment as well as the wound care allograft that HLTT manufactures.
The View Forward
The acquisition of WRH later this month will provide HLTT a soup-to-nuts integration of the facilities required to develop biotechnical products and bring them to market. The only external input necessary for significant growth will be funding. Towards that end, management is in discussions with several broker-dealers with a view toward one or more of them sponsoring the uplist of HLTT’s shares to the NYSE American or NASDAQ. We plan to initiate the uplist process, soon after we file our 10-K Annual Report for 2022.
In sum, management expects 2023 to be HLTT‘s breakout year. We thank you for the support and dedication you have shown the company since 2020. We pledge to work tirelessly to assure that your confidence will be well rewarded.
Sincerely,
Manuel E Iglesias, President
Healthtech Solutions, Inc.
January 6, 2023
We're not above dragooning.
Welcome aboard.
I think it's 150 million tons a year. forty percent of the total crop of 384 million tons.
https://www.statista.com/statistics/686193/production-of-corn-us/
https://civileats.com/2022/02/14/how-corn-ethanol-for-biofuel-fueled-climate-change/
Or from the University of Illinois.
https://farmdocdaily.illinois.edu/2020/03/corn-used-for-ethanol-update.html
5.4 billion bushels per year, 56 pounds in a bushel.
50k tons or 50 tons??
Just curious, as you and I seem to be the only ones here, who are you? I'm an investor in pred who is following HLTT because while PRED gives no info at this time, HLTT seems to give some info on PRED.
Clearly someone is selling, but
We don't know if it is a short, a year end tax loss seller, someone who got some margin calls, or something else. But you may notice is that there is some buying as well. We don't know what is going on, or at least I don't, but we do know that it is year end and the new machine is coming next week.
There will be news about the testing of that machine. They already tested it at the Komarek plant earlier in it's stripped down configuration as I understand it, so there should be no surprises. As I said before, short term price moves don't matter now.
I just wish I had some more money.
Day to day price variation is irrelevant. If they can make this work, we will all do very, very well. If not, well then not.
The markets don't correctly evaluate these stocks on a day to day basis like AAPL or AMZN. If you weren't planning to sell in the next week, then who cares.
Thanks.
It's behind a paywall. Can you tell us what it says?
Thanks for the post.
I do believe they have the technology and it works. The only thing now, is can they bring it home. I'll wait.
HLTT, pred's partner in wound care, posted its 10Q last month. 776k sales of pred's allograft in September. Looks good.
"Sales of our wound care allografts commenced in September 2022, as we delivered allografts to five customers for an aggregate purchase price, net of discounts, of $776,221. Payments for the sales did not commence until October, so we recorded accounts receivable from the sales of $720,777, representing the net sales revenue less an allowance for doubtful accounts of $55,444. After recording $51,834 in cost of goods sold (i.e. proportionate allocation to the products sold of the direct costs attributable to their production), we recorded gross profit of $720,175 for the three and nine months ended September 30, 2022. We expect that in future periods our gross margin ratio will be lower than the ratio we recorded in the periods ended September 30, 2022."
https://www.otcmarkets.com/filing/html?id=16221949&guid=xrG-kWHM7TC6dth
Where do you see quotes?
I know on Think or swim they have the last quotes up from before they went dark, and they never change.